Pembrolizumab with or Without Lenvatinib As First-line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC): Phase 3 LEAP-010 Study

医学 伦瓦提尼 彭布罗利珠单抗 头颈部鳞状细胞癌 肿瘤科 内科学 头颈部癌 头颈部 外科 免疫疗法 放射治疗 癌症 甲状腺癌
作者
Lisa Licitra,Makoto Tahara,Kevin J. Harrington,Mivael Olivera,Yi Guo,Sercan Aksoy,Min Fang,Bogdan Żurawski,Tibor Csöszi,Mikhail Klochikhin,Tainá B. Oliveira,Shunji Takahashi,Muh‐Hwa Yang,Paul Swiecicki,Karen O’Hara,John Paul Shen,Andrew Z. Wang,Burak Gümüşçü,K.C. Benjamin,Robert I. Haddad
出处
期刊:International Journal of Radiation Oncology Biology Physics [Elsevier BV]
卷期号:118 (5): e2-e3 被引量:10
标识
DOI:10.1016/j.ijrobp.2024.01.016
摘要

Purpose/Objective(s) The PD-1 inhibitor pembrolizumab (pembro) is approved as first-line monotherapy for patients (pts) with PD-L1-expressing R/M HNSCC (PD-L1 combined positivity score [CPS] ≥1). A phase 1b/2 study of pembro plus the multikinase inhibitor lenvatinib (len) showed promising antitumor activity and manageable toxicity in pts with HNSCC. In LEAP-010, a phase 3, randomized, placebo-controlled, double-blind study, we hypothesized that first-line len + pembro would improve efficacy compared with placebo + pembro, and have a manageable safety profile, in pts with PD-L1 CPS ≥1 R/M HNSCC (NCT04199104). Materials/Methods Eligible pts had R/M HNSCC incurable by local therapy, PD-L1 CPS ≥1 by central laboratory assessment, known HPV status, and ECOG PS 0 or 1. Pts were randomized 1:1 to len 20 mg or placebo orally once daily plus pembro 200 mg IV Q3W for ≤35 cycles given until intolerable toxicity, progression, or withdrawal. Primary end points were ORR and PFS per RECIST 1.1 by BICR and OS; secondary end points were DOR per RECIST 1.1 by BICR and safety. Per the prespecified analysis plan, ORR and PFS are reported from the first interim analysis (IA1) and OS and DOR are reported from IA2. Data cutoff dates were July 6, 2022 for IA1 and May 30, 2023 for IA2. Results 511 pts were randomized to len + pembro (n = 256) or placebo + pembro (n = 255). Median follow-up (ie, time from randomization to data cutoff) was 11.5 months (mo; range, 0.0-27.6) for IA1 and 21.3 mo (range, 9.0-38.4) for IA2. At IA1, median PFS was 6.2 mo (95% CI: 5.1-7.2) for len + pembro vs 2.8 mo (95% CI: 2.0-4.0) for placebo + pembro (HR: 0.64, 95% CI: 0.50-0.81; P=0.0001040). At IA1 and among the 351 pts with ≥6-mo follow-up, ORR was 46.1% (95% CI: 38.6-53.7) for len + pembro vs 25.4% (95% CI: 19.1-32.6) for placebo + pembro (difference 20.2, 95% CI 10.5-29.6, P=0.0000251). At IA2, median DOR was 10.1 mo (range, 1.3-30.9) for len + pembro vs NR (1.2-32.2) for placebo + pembro. At IA2, the median OS was 15.0 mo (95% CI: 13.2-17.0) for len + pembro vs 17.9 mo (95% CI: 13.8-21.6) for placebo + pembro (HR = 1.15, 95% CI: 0.91-1.45; P=0.882), with respective 24-month OS of 35.7% (95% CI: 29.0-42.4) and 40.0% (95% CI: 32.8-47.1). At IA2, 156 (61.4%) pts on len + pembro had grade ≥3 treatment-related adverse events (TRAEs) vs 45 (17.8%) on placebo + pembro, 28% vs 8% pts discontinued any treatment due to TRAEs, and 7 vs 3 pts had treatment-related deaths, respectively. Conclusion In pts with PD-L1 CPS ≥1 R/M HNSCC, first-line len + pembro significantly improved PFS and ORR, but not OS, compared with pembro alone. The safety profile was consistent with previously reported data; more TRAEs were found in pts receiving len + pembro. Further research is needed to identify effective treatment options for these pts. The PD-1 inhibitor pembrolizumab (pembro) is approved as first-line monotherapy for patients (pts) with PD-L1-expressing R/M HNSCC (PD-L1 combined positivity score [CPS] ≥1). A phase 1b/2 study of pembro plus the multikinase inhibitor lenvatinib (len) showed promising antitumor activity and manageable toxicity in pts with HNSCC. In LEAP-010, a phase 3, randomized, placebo-controlled, double-blind study, we hypothesized that first-line len + pembro would improve efficacy compared with placebo + pembro, and have a manageable safety profile, in pts with PD-L1 CPS ≥1 R/M HNSCC (NCT04199104). Eligible pts had R/M HNSCC incurable by local therapy, PD-L1 CPS ≥1 by central laboratory assessment, known HPV status, and ECOG PS 0 or 1. Pts were randomized 1:1 to len 20 mg or placebo orally once daily plus pembro 200 mg IV Q3W for ≤35 cycles given until intolerable toxicity, progression, or withdrawal. Primary end points were ORR and PFS per RECIST 1.1 by BICR and OS; secondary end points were DOR per RECIST 1.1 by BICR and safety. Per the prespecified analysis plan, ORR and PFS are reported from the first interim analysis (IA1) and OS and DOR are reported from IA2. Data cutoff dates were July 6, 2022 for IA1 and May 30, 2023 for IA2. 511 pts were randomized to len + pembro (n = 256) or placebo + pembro (n = 255). Median follow-up (ie, time from randomization to data cutoff) was 11.5 months (mo; range, 0.0-27.6) for IA1 and 21.3 mo (range, 9.0-38.4) for IA2. At IA1, median PFS was 6.2 mo (95% CI: 5.1-7.2) for len + pembro vs 2.8 mo (95% CI: 2.0-4.0) for placebo + pembro (HR: 0.64, 95% CI: 0.50-0.81; P=0.0001040). At IA1 and among the 351 pts with ≥6-mo follow-up, ORR was 46.1% (95% CI: 38.6-53.7) for len + pembro vs 25.4% (95% CI: 19.1-32.6) for placebo + pembro (difference 20.2, 95% CI 10.5-29.6, P=0.0000251). At IA2, median DOR was 10.1 mo (range, 1.3-30.9) for len + pembro vs NR (1.2-32.2) for placebo + pembro. At IA2, the median OS was 15.0 mo (95% CI: 13.2-17.0) for len + pembro vs 17.9 mo (95% CI: 13.8-21.6) for placebo + pembro (HR = 1.15, 95% CI: 0.91-1.45; P=0.882), with respective 24-month OS of 35.7% (95% CI: 29.0-42.4) and 40.0% (95% CI: 32.8-47.1). At IA2, 156 (61.4%) pts on len + pembro had grade ≥3 treatment-related adverse events (TRAEs) vs 45 (17.8%) on placebo + pembro, 28% vs 8% pts discontinued any treatment due to TRAEs, and 7 vs 3 pts had treatment-related deaths, respectively. In pts with PD-L1 CPS ≥1 R/M HNSCC, first-line len + pembro significantly improved PFS and ORR, but not OS, compared with pembro alone. The safety profile was consistent with previously reported data; more TRAEs were found in pts receiving len + pembro. Further research is needed to identify effective treatment options for these pts.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
潘善若发布了新的文献求助10
1秒前
caicai完成签到,获得积分10
2秒前
CodeCraft应助廉凌波采纳,获得10
3秒前
5秒前
仁爱水之完成签到 ,获得积分10
5秒前
丫丫完成签到,获得积分10
7秒前
7秒前
7秒前
prime发布了新的文献求助10
8秒前
雨过天晴发布了新的文献求助10
9秒前
10秒前
10秒前
10秒前
天天快乐应助玛卡巴卡采纳,获得30
11秒前
xiaohu完成签到,获得积分10
11秒前
zm发布了新的文献求助10
13秒前
温暖的冰菱关注了科研通微信公众号
13秒前
程程发布了新的文献求助10
13秒前
乖猫要努力应助感动黄豆采纳,获得10
14秒前
潘善若发布了新的文献求助10
16秒前
anna发布了新的文献求助10
17秒前
18秒前
充电宝应助momo采纳,获得10
18秒前
勤奋梨愁完成签到,获得积分10
19秒前
summer完成签到,获得积分10
19秒前
20秒前
深情安青应助程程采纳,获得10
22秒前
张雯思发布了新的文献求助10
22秒前
格格完成签到 ,获得积分10
25秒前
25秒前
Hello应助下一秒采纳,获得10
28秒前
天天快乐应助科研通管家采纳,获得10
29秒前
赘婿应助科研通管家采纳,获得10
29秒前
搜集达人应助科研通管家采纳,获得10
29秒前
桐桐应助科研通管家采纳,获得10
29秒前
科研通AI5应助科研通管家采纳,获得10
29秒前
31秒前
31秒前
刘娅铷完成签到,获得积分10
31秒前
32秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989263
求助须知:如何正确求助?哪些是违规求助? 3531418
关于积分的说明 11253814
捐赠科研通 3270066
什么是DOI,文献DOI怎么找? 1804884
邀请新用户注册赠送积分活动 882084
科研通“疑难数据库(出版商)”最低求助积分说明 809136